Chemotherapy after PD-1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics.

Authors:
Calabretta E; Guidetti A; Ricci F; Di Trani M; Monfrini C and 13 more

Journal:
Br J Haematol

Publication Year: 2022

DOI:
10.1111/bjh.18183

PMCID:
PMC9321573

PMID:
35468225

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Br J Haematol

Abbreviation: Br J Haematol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Hematology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Accumulation of foamy macrophages in the bone marrow following chronic intravenous drug use.
Kyla Y; Penelope K; Kerry BM and 1 more (2022) - Transparency Score: 1/6
Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with elt…
Al-Samkari H; Jiang D; Gernsheimer T and 5 more (2022) - Transparency Score: 3/6
Antithrombin-III mitigates thrombin-mediated endothelial cell contraction and sickle red blood cell…
Wulftange WJ; Kucukal E; Man Y and 10 more (2022) - Transparency Score: 4/6
A survey on thromboprophylaxis and coagulation assessment in children and young adults with acute l…
Andersson NG; Rathe M; Mølle I and 12 more (2022) - Transparency Score: 3/6
BCR::ABL1 transcripts and clinical outcome - interrogating the technique.
Branford S. (2022) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
2/6
33.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:

"This work was supported in part by a grant from the Italian Association for Cancer Research (AIRC, grant #20575 to CC‐S)."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025